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Multiple myeloma is the most frequent indication for high-dose melphalan (HDM) chemotherapy with
autologous stem cell transplantation (ASCT). Gastrointestinal symptoms represent the most signiﬁcant
nonhematological toxicity of HDM. However, speciﬁc, especially genetic, predictors of their incidence or
clinical severity are lacking. The amino acid transporters LAT1 and LAT2 encoded by the SLC7A5 and SLC7A8
genes, respectively, are the principal mediators of melphalan uptake into cells. To determine whether genetic
variability at these loci contributed to interindividual differences in the development of gastrointestinal
complications of HDM, we analyzed single nucleotide polymorphisms (SNPs) in these genes in 135 patients
with multiple myeloma treated with HDM and ASCT and correlated these with the need for total parenteral
nutrition (TPN). Seven SNPs in SLC7A5 and 20 in SLC7A8 were genotyped. Multiple analyses indicated that 1
SNP in the ﬁrst intron of SLC7A5, rs4240803, was signiﬁcantly associated with TPN use (odds ratio ¼ .45, 95%
conﬁdence interval, .25 to .79; P ¼ .007). Further, every haplotype that correlated with TPN requirement
included this SNP. These results suggest that variability in melphalan transport affects mucosal injury after
HDM. This ﬁnding could help in individualizing the dose of this effective and widely used chemotherapeutic
agent for multiple myeloma.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The alkylating agent melphalan (or phenylalanine
mustard) has been a key component in the treatment of
multiple myeloma for several decades [1]. Its dose-limiting
toxicities, when used at high doses with autologous stem
cell transplantation (ASCT), include myelosuppression and
gastrointestinal injury, which can manifest in anorexia,
nausea, vomiting, diarrhea, and oral mucositis (OM) [2].
There is extensive interindividual variation in melpha-
lan’s pharmacokinetics, both for intravenous and oral
administration [3]. Further, the frequency and severity of
OM, while somewhat dose-related, show considerable vari-
ability between patients receiving an identical high dose ofedgments on page 1020.
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14.03.022melphalan. Genetic differences have been proposed to be
responsible [4].
L-type amino acid transporters 1 (LAT1) and 2 (LAT2) are
responsible for the transport of large neutral amino acids
into the cell. These integralmembrane proteins form obligate
heterodimers of a catalytic light chain (LAT1 or LAT2) and
glycoprotein heavy chain, 4F2hc/CD98 [5]. High levels of
SLC7A5 mRNA encoding the LAT1 transporter have been
noted inmost human tissues, except for the intestine [6], and
LAT1 is thought to play a key role in amino acid uptake by
dividing cells. Further, SLC7A5 expression is upregulated in
multiple tumor types [7], which may contribute to their
abnormal phenotype.
In contrast to the broad expression of LAT1, LAT2 is
restricted primarily to the kidneys and bowel [8], where it
localizes to basolateral membranes and likely functions in
epithelial amino acid reabsorption.
Melphalan resembles phenylalanine in its afﬁnity for
LAT1 and LAT2, which mediate the transport of both intoTransplantation.
Table 2
Minor Allele Frequencies of Markers Analyzed
Gene Marker Minor Allele Frequency
SLC7A5 rs1060253 G .2889
SLC7A5 rs3815559 C .2037
SLC7A5 rs12931876 C .1374
SLC7A5 rs4843718 A .2519
SLC7A5 rs731710 C .3667
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polymorphisms in the SLC7A5 or SLC7A8 genes encoding the
catalytic subunits of LAT1 and LAT2, respectively, associate
with development of gastrointestinal toxicity after high-dose
melphalan (HDM). It revealed a signiﬁcant association be-
tween 1 SNP, rs4240803, located in the ﬁrst intron of SLC7A5,
and the need for total parenteral nutrition (TPN) in a series of
patients with multiple myeloma from multiple institutions
who were treated with HDM and ASCT.
MATERIALS AND METHODS
Patients
All subjects carried a diagnosis of multiple myeloma and were treated at
Vanderbilt University Medical Center (n ¼ 114), the Nashville VA Medical
Campus of the Tennessee Valley Healthcare System (n ¼ 8), the University
of Texas Health Sciences Center San Antonio, or the Audie L. Murphy VA
Hospital of San Antonio Veterans Health Care System (n¼ 13). They could be
enrolled before or after treatment with HDM chemotherapy and ASCT was
initiated. This study was approved by the responsible institutional review
boards at Vanderbilt University Medical Center, University of Texas Health
Science Center at San Antonio, and at the Nashville and San Antonio VA
Medical Centers. Informed consent was obtained from all patients before
entry. Exclusion criteria included a diagnosis other than multiple myeloma,
previous treatment with HDM, and receipt of recombinant human kerati-
nocyte or ﬁbroblast growth factor.
One hundred and thirty-ﬁve Caucasian patients (95 males and 40 fe-
males) were included in this analysis. Patient characteristics at entry are
listed in Table 1. Peripheral blood samples for DNA extractionwere collected
at the time of patient enrollment. Patients who received TPN at any time
during the ﬁrst 14 days after transplantation were deﬁned as cases (75 pa-
tients, including 43 males and 32 females), whereas patients who did not
receive TPN were treated as controls (60 patients, including 52 males and 8
females).
Treatment
HDMwas given in 2 divided doses via an intravenous route 3 and 2 days
before transplantation. Total doses of 140 mg/m2 (n ¼ 11) or 200 mg/m2
(n ¼ 124) of melphalan were administered. Patients received previously
cryopreserved apheresed peripheral blood stem cells within a range of 2 to
4  106 CD34þ cells/kg of body weight.
Phenotypic Assessment of Gastrointestinal Toxicity
Requirement for TPN provided a global measure of gastrointestinal
toxicity and served as a proxy for chemotherapy-induced mucositis. The
indications for TPN use were similar for all centers and included odyno-
phagia requiring administration of narcotic analgesics, severe diarrhea, or
inability to eat. Information on the use of TPN after HDM chemotherapy and
ASCT was collected on every subject. Use of TPN as an index of gastroin-
testinal toxicity has the signal advantage of encompassing all of its clinical
manifestations, including pain, nausea, and diarrhea; is robust to observer
bias; and can be accurately assessed in every patient, either prospectively or
retrospectively. For these reasons, TPN requirement was used as the major
phenotypic endpoint in our study.Table 1
Patient Demographics and Melphalan Regimen
Characteristic Cases Controls P Value
Study participants 75 60
Study participants by
gender (% female)
42.67% 13.33% .00002*
Age, mean, yr 57.52 (.76)y 57.35 (.98)y .7970z
Melphalan dose, mean
(mg/m2)
196.00 (1.95)y 195.14 (1.92)y .7531z
Body mass index, mean 28.92 (.53)y 30.23 (.95)y .8231z
Pretreatment chemotherapy
(% receiving VAD)
10.67% 3.33% .1056*
VAD indicates a speciﬁc chemotherapy regimen that includes vincristine,
doxorubicin, and dexamethasone.
* P value presented is from the 2 sample differences of proportions test
performed in STATA.
y Standard error of the mean.
z P value presented is from the Wilcoxon rank-sum test performed in
STATA.DNA Genotyping and Quality Control
A total of 32 SNPs from the SLC7A5 and SLC7A8 genes were genotyped.
These SNPs were selected from their ability to tag nearby variants in the
HapMap database (http://www.hapmap.org) using Caucasian samples. An r2
of .80 and a minor allele frequency of .10 were used as tagging criteria.
Genotyping was performed with the Sequenom MASSarray system in the
Vanderbilt University Center for Human Genetics Research Core Laboratory,
according to the manufacturer’s protocol. Ambiguous calls by the software
were resolved by inspection by laboratory personnel and investigators. Of
the 32 SNPs genotyped, 27 passed quality control, with a genotyping efﬁ-
ciency of greater than 95%. Seven of the SNPs analyzed were from SLC7A5
and 20 were located in SLC7A8 (Table 2).
Statistical Analysis
Before analyses for association, all SNPs that could be successfully
genotyped were checked for deviations from Hardy-Weinberg equilibrium
using the Willington’s exact test in PLINK version 1.07 software (http://
pngu.mgh.harvard.edu/purcell/plink/) [11], and the results were conﬁrmed
with the PLATO software package (http://ritchielab.psu.edu/ritchielab/
project-plato/) [12]. Tests were carried out on the entire dataset, as well as
on cases and controls independently. Linkage disequilibrium between
markers in SLC7A5 (n ¼ 7) and SLC7A8 (n ¼ 20) was measured using release
4.2 of the software package Haploview (http://haploview@broad.mit.edu)
[13]. This was measured in the full dataset, as well as in case and control
groups separately (Supplemental Figures 1A-3B).
Genotype-phenotype associations were tested using 4 methods. First,
single SNP association was analyzed with Fisher’s exact test of association
using PLINK [11], both for the full dataset and a subset containing only male
subjects. Females were not analyzed separately because of their small
sample size; however, adjustment for gender was carried out, where
possible, to account for effects. Second, exact logistic regression analysis was
used to test for single SNP association with those SNPs shown to be signif-
icant in the prior analysis. The results of both analyses are presented. Exact
logistic regression analysis was carried out using release 10 of the software
package STATA (StataCorp LP, College Station, TX), which also estimated odd
ratios. Third, a prevalence-based association test (PRAT) was used to validate
logistic regression single SNP analyses [14]. PRAT analysis, which is based on
Hardy-Weinberg principles, compared expected case and control genotype
frequency distributions against expected values estimated from the preva-
lence of phenotypes and allele frequencies within case and control groups.
Permutation testing (n ¼ 1000) was used to correct for multiple testing.
Finally, 2, 3, and 4 SNP window haplotype analysis was performed for
SLC7A5 and SLC7A8 separately, using UNPHASED [15] to test for multilocus
effects on TPN use. Only common haplotypes with frequencies  .05 in
either cases or controls were included in our analyses. Odds ratios reportedSLC7A5 rs4240803 A .2815
SLC7A5 rs17853938 T .1000
SLC7A8 rs2331937 T .2630
SLC7A8 rs8011016 C .2333
SLC7A8 rs4982736 A .1852
SLC7A8 rs10150592 A .1852
SLC7A8 rs12894506 T .2293
SLC7A8 rs6573011 G .2594
SLC7A8 rs1983698 T .1407
SLC7A8 rs1884545 T .1111
SLC7A8 rs910795 C .1519
SLC7A8 rs10143650 T .2841
SLC7A8 rs10145863 A .1333
SLC7A8 rs10132368 A .1296
SLC7A8 rs2239628 G .1481
SLC7A8 rs7157207 G .2741
SLC7A8 rs6572981 A .2037
SLC7A8 rs3783436 C .3545
SLC7A8 rs4982732 G .2111
SCL7A8 rs1015089 T .3593
SLC7A8 rs2013931 C .4037
SLC7A8 rs999165 T .2164
Table 3A
Genotype Distributions and Association Results for SLC7A5/SLC7A8 with TPN Use in the Full Dataset
Gene SNP Alleles Min/Max Controls (n)* Cases (n)* Genotypic P Value Allelic P Value
11 12 22 11 12 22
SLC7A5 rs1060253 G/C 5 26 29 4 34 37 .8270 .7873
rs3815559 C/G 3 20 37 4 21 50 .8706 .6511
rs12931876 C/T 2 14 43 2 14 56 .8759 .5897
rs4843718 A/G 5 23 32 7 21 47 .4686 .4814
rs731710 C/T 11 28 21 9 31 35 .3371 .1301
rs4240803 A/G 7 30 23 3 26 46 .0178 .0064
rs17853938 T/G 1 10 49 0 15 60 .6468 1.0000
SLC7A8 rs2239628 G/A 0 15 45 3 19 53 .3988 .3907
rs7157207 G/T 3 27 30 6 29 40 .6531 1.0000
rs6572981 A/G 0 23 37 4 24 47 .1856 .7613
rs3783436 C/T 12 22 26 8 33 33 .3252 .4412
rs4982732 G/C 2 19 39 3 28 44 .7774 .5493
rs1015089 T/G 4 32 24 13 31 31 .1283 .4463
rs2013931 C/T 12 24 24 13 35 27 .7632 1.0000
rs999165 T/A 3 21 36 3 25 46 .9553 .7676
rs2331937 T/C 3 23 34 7 28 40 .7123 .4905
rs8011016 C/T 5 17 38 2 32 41 .1171 .8850
rs4982736 A/G 3 20 37 3 18 54 .4517 .2706
rs10150592 A/C 3 19 38 3 19 53 .6683 .4316
rs910795 C/T 2 16 42 3 15 57 .7092 .6098
rs10143650 T/C 4 20 36 5 29 41 .8556 .6716
rs10145863 A/G 1 13 46 0 21 54 .4218 .8573
rs12894506 T/C 2 20 37 4 29 41 .7152 .3829
rs6573011 G/A 3 21 36 5 32 36 .4790 .2635
rs10132368 A/G 1 10 49 3 17 55 .5453 .2078
rs1983698 T/C 0 18 42 1 18 56 .6851 .7271
rs1884545 T/C 0 16 44 2 10 63 .0620 .3333
P values in bold remained signiﬁcant after correction for multiple testing.
P values shown are Fisher’s exact P values.
* Genotype key e 11: homozygous minor; 12: heterozygous; 22: homozygous major.
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relative to the reference haplotype, and the most common haplotype was
used as the reference in our analyses. Permutation (n ¼ 1000) was used toTable 3B
Genotype Distributions and Association Results for SLC7A5/SLC7A8 with TPN Use in
Gene SNP Alleles Min/Max Controls (n)*
11 12 22
SLC7A5 rs1060253 G/C 4 23 25
rs3815559 C/G 2 18 32
rs12931876 C/T 1 13 37
rs4843718 A/G 4 20 28
rs731710 C/T 10 24 18
rs4240803 A/G 6 28 18
rs17853938 T/G 0 10 42
SLC7A8 rs2239628 G/A 0 14 38
rs7157207 G/T 3 25 24
rs6572981 A/G 0 21 31
rs3783436 C/T 10 21 21
rs4982732 G/C 2 15 35
rs1015089 T/G 3 27 22
rs2013931 C/T 10 22 20
rs999165 T/A 0 19 33
rs2331937 T/C 3 20 29
rs8011016 C/T 5 14 33
rs4982736 A/G 3 19 30
rs10150592 A/C 3 18 31
rs910795 C/T 2 15 35
rs10143650 T/C 4 18 30
rs10145863 A/G 1 12 39
rs12894506 T/C 2 18 31
rs6573011 G/A 3 20 29
rs10132368 A/G 1 10 41
rs1983698 T/C 0 17 35
rs1884545 T/C 0 15 37
TPN indicates total parenteral nutrition.
P values in bold remained signiﬁcant after correction for multiple testing.
P values shown are Fisher’s exact P values.
* Genotype key e 11: homozygous minor; 12: heterozygous; 22: homozygous mcorrect for multiple testing in individual haplotype tests. A ﬁgure summa-
rizing study design and the analyses employed is included in Supplemental
Materials (Supplemental Figure 4).Males Only
Cases (n)* Genotypic P Value Allelic P Value
11 12 22
2 18 23 .8489 .6262
3 10 30 .4325 .7178
1 6 35 .4364 .372
5 9 29 .1764 .5010
6 15 22 .2762 .1341
2 14 27 .0229 .0112
0 7 36 .7920 .8022
3 10 30 .1985 .4245
5 17 21 .5303 .8747
3 14 26 .1406 .7234
2 19 22 .1064 .0895
2 18 23 .3558 .2878
10 19 14 .0493 .0712
4 22 17 .3937 .4563
1 13 29 .5100 1.0000
6 15 22 .4433 .3353
2 18 23 .7969 .8631
3 13 27 .7969 .8631
3 14 26 1.0000 1.0000
3 12 28 .8252 .7141
4 21 18 .2988 .2018
0 13 30 .6377 .8355
3 22 18 .1879 .0996
2 23 17 .2965 .3287
1 13 29 .4615 .2983
1 8 34 .1612 .4079
1 4 38 .0212 .1619
ajor.
Table 5A
Prevalence-based Association Test (PRAT) Results in Full Dataset
Gene SNP PRAT P Value
(Cases)*
PRAT P Value
(Controls)y
SLC7A5 rs1060253 .5800 .9520
rs3815559 .6370 1.0000
rs12931876 .6710 .6770
rs4843718 .3370 .8840
rs731710 .2230 .6310
rs4240803 .0070 .2210
rs17853938 .6740 .7640
SLC7A8 rs2239628 .3020 .2010
rs7157207 1.0000 .2750
rs6572981 .8420 .0440
rs3783436 .7430 .0860
rs4982732 .6230 .9170
rs1015089 .3060 .0430
rs2013931 .9890 .2400
rs999165 .9110 1.0000
rs2331937 .5280 .7450
rs8011016 .2320 .0720
rs4982736 .3780 .8180
rs10150592 .5590 .8090
rs910795 .5300 .8970
rs10143650 .8040 .6230
rs10145863 .2840 .9380
rs12894506 .5480 .7090
rs6573011 .3340 .7510
rs10132368 .2170 .7090
rs1983698 .9120 .1520
rs1884545 .1250 .1100
P values in bold remained signiﬁcant after correction for multiple testing.
* PRAT P values in cases only based on 1000 permutations.
y PRAT P values in controls only based on 1000 permutations.
Table 5B
Prevalence-based Association Test (PRAT) Results in Males-Only Subset
Gene SNP PRAT P Value
(Cases)*
PRAT P Value
(Controls)y
SLC7A5 rs1060253 .6580 .7080
rs3815559 .3740 .9250
rs12931876 .3610 .7710
rs4843718 .2050 .9690
rs731710 .1930 .6900
rs4240803 .0110 .0970
rs17853938 1.0000 .4940
SLC7A8 rs2239628 .1090 .2210
rs7157207 .8400 .2080
rs6572981 .6800 .0490
rs3783436 .1520 .0940
rs4982732 .3080 .6190
rs1015089 .0460 .0290
rs2013931 .5210 .2530
rs999165 1.0000 .1830
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Subject Demographics and Clinical Characteristics
Cases and controls were well matched, without statisti-
cally signiﬁcant differences in mean age or melphalan dose
(Table 1). They did differ, however, in gender distribution
(P ¼ .0021), with a signiﬁcantly higher proportion of females
in the group that received TPN (cases) than in the group that
did not (controls).
Single-Locus Association Analysis
None of the 27 genetic markers that passed quality
control deviated signiﬁcantly from Hardy-Weinberg equi-
librium (Supplemental Table 1). Allelic and genotypic asso-
ciations with TPN use were investigated by Fisher’s exact
test. This revealed that of the 7 SNPs analyzed in SLC7A5,
only 1 marker, rs4240803, correlated signiﬁcantly with the
use of TPN in both allelic (P ¼ .0064) and genotypic
(P ¼ .0178) analyses (Table 3A). After false discovery rate
(FDR) correction, rs4240803 remained associated with TPN
requirement in allelic but not genotypic testing. In contrast,
none of 20 markers in SLC7A8 were associated with TPN
administration (Table 3A). When the analysis was restricted
to males only, 3 SNPs, 2 in SLC7A5 and 1 in SLC7A8, were
found to have signiﬁcant allelic and/or genotypic associa-
tions with TPN use (Table 3B). The most highly associated in
the male-only dataset was rs4240803 (P ¼ .0112 for allelic
testing and P ¼ .0229 for genotypic testing). In addition, 2
markers in SLC7A8, rs1884545 (P ¼ .0212 in genotypic
testing) and rs1015089, were associated with TPN require-
ment (P ¼ .0493 in genotypic testing), although less signif-
icantly. However, after FDR correction for multiple testing,
only SNP rs4242803 was still associated with TPN use (for
males).
Univariate exact logistic regression analysis was carried
out for all SNPs found to be signiﬁcantly associated with
clinical phenotype in Fisher’s exact analysis, both for the
complete dataset and for males only (Table 4). The reference
genotype in this analysis was the homozygote for the major
allele. Analysis of the full dataset showed that rs4240803was
signiﬁcantly associated with TPN use (odds ratio ¼ .45; 95%
CI, .25 to .79; P ¼ .007). Of the 3 SNPs that were associated
with TPN requirement in males, rs4240803, rs1015089, and
rs1884545 (in SLC7A8), only rs4240803 was signiﬁcantly
associated in exact logistic regression analysis (odds
ratio¼ .40; 95% CI, .19 to .80; P¼ .011). The most signiﬁcantly
associating SNP in the complete dataset, rs4240803, showed
slightly lower, although still signiﬁcant, association when
analysis was restricted to males for either analytical method,
suggesting that the genetic effect trended in the same di-
rection for both genders and that signiﬁcance was likely
decreased by the reduction in sample size after ﬁltering out
female participants. However, the discovery of markers inTable 4
Logistic Regression Results for Full and Male-only Datasets
SNP Dataset
Analyzed*
Odds
Ratio
95% Conﬁdence
Interval
P Value
SLC7A5
rs4240803 Full .45 .25-.79 .007
Male only .40 .19-.80 .011
SLC7A8
rs1015089 Male only 1.83 .95-3.63 .072
rs1884545 Male only .44 .13-1.29 .158
* Denotes the dataset in which each logistic regression analysis was
performed.SLC7A8 that associated with TPN in the male-only subset, but
not the full dataset, suggest that the genetic effects of these
markers could differ by gender; however, such a conclusion
is at present unwarranted.rs2331937 .2360 .8490
rs8011016 .7140 .0710
rs4982736 .6870 1.0000
rs10150592 .8580 .9460
rs910795 .6090 .9240
rs10143650 .2740 .3980
rs10145863 .3490 .8930
rs12894506 .0670 .5720
rs6573011 .1350 .8910
rs10132368 .4830 .6360
rs1983698 .5190 .0590
rs1884545 .0590 .0120
P values in bold remained signiﬁcant after correction for multiple testing.
* PRAT P values in cases based on 1000 permutations.
y PRAT P values in controls only based on 1000 permutations.
Figure 1. Graphical representation of signiﬁcant haplotype associations for
SLC7A5 markers. Black lines denote the haplotypes with a value of P < 0.01 for
the Global Likelihood Ratio test performed using UNPHASED. This tested the
null hypothesis that the haplotype including a given set of markers would not
be associated with TPN use. Red lines denote haplotypes that remained sig-
niﬁcant after correction for multiple testing. All of the signiﬁcantly associating
haplotypes included SNP rs4240803.
J.L. Giglia et al. / Biol Blood Marrow Transplant 20 (2014) 1014e10201018The association between the SNPs in SLC7A5 and SLC7A8
and TPN requirement was also analyzed by PRAT (Tables 5A
and 5B), which serves to validate associations detected us-
ing logistic regression analysis. PRAT analysis of the full
dataset identiﬁed 3 SNPs associated with TPN use
(Table 5A). Two of the markers were discovered in previous
analyses, rs4240803 and rs1015089, whereas a third, novel
association was uncovered for rs6572981 in SLC7A8. The
single SLC7A5 SNP rs4240803 showed a signiﬁcant associ-
ation only for cases (P ¼ .0070) and was the most signiﬁ-
cantly associated SNP in PRAT analysis of the full dataset.
Rs1015089 and rs6572981 were marginally signiﬁcant in
controls only, with P ¼ .043 and P ¼ .044, respectively. PRAT
analysis in the male-only subset (Table 5B) conﬁrmed the
signiﬁcant association between rs4240803 and TPN use
(P ¼ .011 in cases), whereas rs6572981 was marginally sig-
niﬁcant (P ¼ .049). In contrast to the results with the full
dataset, rs1015089 became more signiﬁcant in controls
(P ¼ .029) and displayed only marginal signiﬁcance in cases
(P ¼ .046). In addition, rs1884545, which was not identiﬁed
in previous PRAT analysis of the full dataset, was found to be
associated with TPN requirement in PRAT analysis of males
(P ¼ .012).Table 6A
Signiﬁcant Two-Locus Haplotype Associations in the SLC7A5 Gene with Use of TPN
SNPs Haplotype Frequency Cases Frequency
rs731710-rs4240803
Reference haplotype C-A .1304 .5551
C-G .1963 .0496
T-A .083 .3382
T-G .5094 .0541
rs4240803-rs17853938
Reference haplotype A-G .2133 .3507
A-T .0000 .0160
G-G .6867 .5493
G-T .1000 .0840
TPN indicates total parenteral nutrition.
P values in bold remained signiﬁcant after correction for multiple testing.
Rare haplotype (frequency < .05 in either cases or controls) excluded from individ
* P value for each individual haplotype versus all others based on UNPHASED sc
y Global P value for a particular group of loci.
z Odds ratio is statistically signiﬁcant.Haplotype Analysis
Haplotype association testing with 2 to 4 SNP sliding
windows was performed on the full dataset using
UNPHASED. Signiﬁcant haplotype associations were discov-
ered only for SLC7A5 (Figure 1) (Table 6A-C). The haplotype
most highly associated with TPN usewas a 4-locus haplotype
comprised of rs4843718, rs731710, rs4240803, and
rs17853938 (C-C-A-G).
The association with TPN requirement (P ¼ .003)
remained signiﬁcant even after correction for multiple
testing. Importantly, each of the 6 haplotypes that was
associated with TPN use included rs4240803, indicating that
all of the haplotype effects observed were driven by this SNP.
DISCUSSION
After myelosuppression, gastrointestinal injury is the
most frequent toxicity of HDM and ASCT. The development of
mucositis in this setting translates into an increased risk of
infection, requirement for parenteral nutrition and intrave-
nous narcotics, greater expense, longer hospitalization, and,
possibly, higher mortality [16].
Our study identiﬁed a SNP in the ﬁrst intron of the SLC7A5
gene, rs4240803, which was associated with a requirement
for TPN in patients who received HDM and ASCT for multiple
myeloma. The signiﬁcance of this SNP was demonstrated in
both allelic and genotypic analysis and remained signiﬁcant
after FDR correction in allelic testing. Independently, haplo-
type association analysis indicated that multilocus effects
were largely due to rs4240803. The association between this
SNP and TPN use, which was conﬁrmed in exact logistic
regression analysis and validatedwith PRATanalysis, was also
signiﬁcant inmale subjects only, suggesting that the direction
of the genetic effect was the same for both genders. Inter-
estingly, therewas anothermarker in our analyses, rs1884545
(in SLC7A8), for which a signiﬁcant association was identiﬁed
in the male-only subset. However, females were under-
represented in our study population as a result of 2 of the 4
study locations being situated in VA medical centers, where
the majority of patients are male, thereby precluding any
deﬁnitive conclusions about gene by gender effects.
TPN requirement was utilized as the primary clinical
endpoint, both because it encompasses injury arising any-
where within the gastrointestinal tract and because it is well
suited to retrospective and prospective analysis of toxicity.
Additionally, the lack of availability of formal mucositis
scores for the majority of our study population and theControls Odds Ratio 95% Conﬁdence Interval P Value*
.0344y
1.00 1.00-1.00 .0048
2.72 1.10-6.72 .3731
1.73 .60-5.37 .4481
2.51z 1.28-4.89 .0540
.0287y
1.00 1.00-1.00 .0087
- - -
2.06z 1.17-3.60 .0157
1.96 .77-4.99 .7472
ual haplotype analysis.
ore statistic.
Table 6B
Signiﬁcant Three-Locus Haplotype Associations in the SLC7A5 Gene with Use of TPN
SNPs Haplotype Frequency Cases Frequency Controls Odds Ratio 95% Conﬁdence Interval P Value*
rs4843718-rs731710-rs4240803 .0099y
Reference haplotype T-T-G .5845 .4837 1.00 1.00-1.00 .0687
C-C-G .0815 .0230 2.93 .62-13.81 .1084
C-T-G .0183 .0000 - - -
T-C-A .1055 .1338 .65 .29-1.47 .2468
T-C-G .1143 .1289 .73 .32-1.70 .9366
T-T-A .0708 .1011 .58 .21-1.61 .2651
C-C-A .0252 .1295 .16z .04-.62 .0034
rs731710-rs4240803-rs17853938 .1102y
Reference haplotype T-G-G .5285 .4346 1.00 1.00-1.00 0.755
C-A-G .1312 .2670 .40z .20-.80 .0055
C-G-G .1582 .1086 1.20 .51-2.80 .3117
C-G-T .0373 .0411 - - -
T-A-G .0822 .899 .75 .28-2.03 .5897
T-A-T .0000 .0098 - - -
T-G-T .0627 .0491 1.05 .30-3.65 .6799
TPN indicated total parenteral nutrition.
P values in bold remained signiﬁcant after correction for multiple testing.
Rare haplotype (frequency < .05 in either cases or controls) excluded from individual haplotype analysis.
* P value for each individual haplotype versus all others based on UNPHASED score statistic.
y Global P value for a particular group of loci.
z Odds ratio is statistically signiﬁcant.
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real consideration as 4 transplantation units afﬁliated with 2
different medical centers were utilized in this study, also
served to reduce the value of utilizing, for example, the Oral
Mucositis Assessment (OMAS) or World Health Organization
scales for phenotypic analysis. However, we acknowledge
that these scales have been experimentally validated and,
therefore, carried out an exploratory analysis of patients
where such data was collected to assess whether OMAS
scores, and, by proxy, severity of mucositis was inﬂuenced by
rs4240803.Table 6C
Signiﬁcant Four-Locus Haplotype Associations in the SLC7A5 Gene with Use of TPN
SNPs Haplotype Frequency Cases Frequency
rs12931876-rs4843718-rs731710-rs4240803
Reference haplotype G-T-T-G .5878 .4838
C-C-C-A .0269 .1294
C-C-C-G .0832 .0231
C-T-C-A .0204 .0313
C-T-C-G .0432 .0280
G-C-T-G .0149 .0000
G-T-C-A .0832 .1027
G-T-C-G .0696 .1007
G-T-T-A .0709 .1009
rs4843718-rs731710-rs4240803-rs17853938
Reference haplotype T-T-G-G .518 .4404
C-C-A-G .0240 .1299
C-C-G-G .0822 .0227
C-T-G-G .0188 .0000
T-C-A-G .1064 .1172
T-C-A-T .0000 .0164
T-C-G-G .0747 .0873
T-C-G-T .0391 .0418
T-T-A-G .0710 .1009
T-T-G-T .0650 .0435
TPN indicated total parenteral nutrition.
P values in bold remained signiﬁcant after correction for multiple testing.
Rare haplotype (frequency < .05 in either cases or controls) excluded from individ
* P value for each individual haplotype versus all others based on UNPHASED sc
y Global P value for a particular group of loci. I is derived from a likelihood rati
controls and tests hypothesis that none of the haplotypes for a given set of loci ar
z Odds ratio is statistically signiﬁcant.This analysis, which could be carried out for only a mi-
nority of subjects, revealed thatmaximumOMAS score during
treatment was signiﬁcantly associated with rs4240803 ge-
notype (P ¼ .003) (Supplemental Material).
Finally, as LAT1 protein is expressed on endothelial cells
that contribute to the blood-brain barrier, it is possible that
melphalan transport into the central nervous system corre-
latedwith transport into epithelial cells in thegut, contributing
to nausea and anorexia and thereby also affecting TPN use.
These results, at least indirectly, underscore the impor-
tance of LAT1 as the major transporter of melphalan intoControls Odds Ratio 95% Conﬁdence Interval P Value*
.0232y
1.00 1.00-1.00 .0673
.17z .05-.62 .0036
2.97 .63-13.95 .1036
- - -
- - -
- - -
.67 .27-1.64 .3718
.57 .22-1.50 .5288
.58 .21-1.61 .2581
.0248y
1.00 1.00-1.00 .1223
.16z .04-.64 .0031
3.08 .65-14.57 .0942
- - -
.77 .33-1.81 .4429
- - -
.73 .26-2.07 .9256
- - -
.60 .21-1.67 .2630
1.27 .36-4.47 .5210
ual haplotype analysis.
ore statistic.
o test comparing the overall distribution of haplotypes between cases and
e associated with TPN use.
J.L. Giglia et al. / Biol Blood Marrow Transplant 20 (2014) 1014e10201020cells, and localization of SNP rs4240803 within the ﬁrst
intron of the SLC7A5 gene close by a region bearing an
epigenetic signature of a transcriptional enhancer (data not
shown) has direct implications for mechanism. Either by
contributing to or, more likely, in linkage with a poly-
morphism affecting the binding of a transcription factor to
this putative enhancer, genetic variation could affect SLC7A5
transcription, membrane expression of LAT1, and ultimately
melphalan transport into gastrointestinal epithelial cells.
Alternatively, the polymorphism could affect drug pharma-
cokinetics, and although LAT1-mediated cellular uptake
could also affect drug handling, it should be noted that no
association between drug pharmacokinetics and toxicity has
been observed [3].
As our work was underway, a similarly designed study
was published that failed to detect an association between
SNPs in the genes encoding LAT1, LAT2, and 4F2hc and
gastrointestinal toxicity after HDM chemotherapy [17].
Although the patient population used was more heteroge-
neous than our’s and included individuals with diseases
other than multiple myeloma, the more likely reason for
these discrepant results was the lack of representation in
their analysis of SNPs from the very large ﬁrst intron of
SLC7A5.
An important implication of this work is the existence of
pharmacogenetic determinants of toxicity of HDM, which
could prove valuable in individualizing drug dose. This study
involved both prospectively and retrospectively acquired
data, and the association between SNP rs4240803, and
possibly several other markers in SLC7A5 and SLC7A8, and
gastrointestinal toxicity after HDM, measured by TPN use
and/or mucositis grade, requires validation in another pa-
tient population in which data are acquired in a wholly
prospective fashion. Such a study is underway, together with
a systematic analysis of SLC7A5 intronic sequences for
enhancer function.
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